




RealRate

PHARMACEUTICAL 2024

Crescent Biopharma INC
Rank 100 of 309

GlycoMimetics, Inc.
Innovation Today, Healing Tomorrow.



The relative strengths and weaknesses of Crescent Biopharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Crescent Biopharma INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 141% points. The greatest weakness of Crescent Biopharma INC is the variable Net Income, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is 282%, being 69% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	43,791
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,835
Liabilities, Non-Current	67
Other Assets	1,526
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	10
Property and Equipment	0
Research and Development	20,072
Selling, General and Administrative Expense	19,214

Output Variable	Value in 1000 USD
Assets	45,316
Liabilities	6,902
Expenses	39,285
Revenues	10
Stockholders Equity	38,414
Net Income	-39,275
Comprehensive Net Income	-39,275
BaseVar	45,757
ECR before Limited Liability	170%
Economic Capital Ratio	282%